Biopharmaceutical Industry Approaches to Facility Segregation for Viral Safety: An Effort from the Consortium on Adventitious Agent Contamination in Biomanufacturing.
Adventitious agent contamination
Facility segregation
Functionally closed
Open ballroom
Physical segregation
Viral clearance
Journal
PDA journal of pharmaceutical science and technology
ISSN: 1948-2124
Titre abrégé: PDA J Pharm Sci Technol
Pays: United States
ID NLM: 9439538
Informations de publication
Date de publication:
Historique:
pubmed:
27
10
2018
medline:
31
5
2019
entrez:
27
10
2018
Statut:
ppublish
Résumé
Appropriate segregation within manufacturing facilities is required by regulators and utilized by manufacturers to ensure that the final product has not been contaminated with (a) adventitious viruses, (b) another pre-/postviral clearance fraction of the same product, or (c) another product processed in the same facility. However, there is no consensus on what constitutes appropriate facility segregation to minimize these risks. In part, this is due to the fact that a wide variety of manufacturing facilities and operational practices exist, including single-product and multiproduct manufacturing, using traditional segregation strategies with separate rooms for specific operations that may use stainless steel or disposable equipment to more modern ballroom-style operations that use mostly disposable equipment (i.e., pre- and postviral clearance manufacturing operations are
Identifiants
pubmed: 30361281
pii: pdajpst.2018.008862
doi: 10.5731/pdajpst.2018.008862
doi:
Substances chimiques
Biological Products
0
Recombinant Proteins
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
191-203Informations de copyright
© PDA, Inc. 2019.